This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Alphatec Spine Announces Third Quarter 2010 Revenue And Financial Results

  • Revenue of $44.8 million; 49% growth over 3Q 2009; Pro Forma Revenue Growth of 2% over 3Q 2009 and 2.3% Growth on a Constant-Currency Basis
  • Adjusted EBITDA of $5.3 million; 11.9% growth over 3Q 2009
  • Non-GAAP Net Earnings of $0.7 million; or $0.01 per share

CARLSBAD, Calif., Nov. 8, 2010 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine, announced today financial results for the fiscal quarter ended September 30, 2010.

Third Quarter 2010 Performance Highlights
  • Achieved US revenues of $30.0 million, representing 15.2% year-over-year growth on a GAAP basis, and 3.4% year-over-year growth on a pro forma basis.
  • Launched PureGen™, the Company's Osteoprogenitor Cell Allograft with the first case completed in September.
  • Established Biologics Division at Alphatec Spine, with the addition of Edward Ross, Vice President and General Manager, Biologics as well as dedicated sales specialists to drive biologics product adoption and work with customers as biologics experts.
  • Strengthened US sales network with the addition of several independent distribution agents and direct representatives in key strategic markets.
  • OsseoFix™, the Company's proprietary device for treating vertebral compression fractures and restoration of vertebral height, has been used in over 1,600 patients in Europe through 3Q 2010, representing continued acceleration in product adoption.
  • OsseoScrew™, the Company's proprietary expandable pedicle screw system, has been used in over 100 patients in Europe through 3Q 2010.
  • Helifix™ Interspinous Spacer System, a proprietary minimally invasive non-fusion solution for lumbar spinal stenosis, was launched in Europe with the first cases completed in Switzerland and Germany.
  • Solus™ ALIF System, a zero-profile, single-action locking implant that is used in anterior lumbar interbody fusion (ALIF) procedures, was launched in Europe with the first cases completed in Germany. 
  • The Company resubmitted the Solus 510(k) application with a revised indication in the third quarter 2010.

Dirk Kuyper, the Company's President and Chief Executive Officer, stated: "I am proud of the focus of the Alphatec Spine team and our ability to achieve continued revenue growth through execution and key product launches despite the challenges currently facing the spine market." Mr. Kuyper continued, "2010 has been a transformative year for the Company and in the third quarter we saw a stabilization of our business internationally and a stabilization of pricing here in the US. The Scient'x integration is progressing, and with the launch of PureGen and most of our key technologies in Europe, we are well positioned as we enter 2011 to drive towards our goal of being the leading global pure-play spine company. We have the team, the products and the strategic plan to achieve long-term revenue growth and enhanced profitability."

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.24 -0.41%
FB $117.81 -0.21%
GOOG $701.43 0.82%
TSLA $211.53 -4.96%
YHOO $36.94 2.61%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs